Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of “Hold” from Analysts

Heron Therapeutics, Inc. (NASDAQ:HRTX) has been assigned a consensus rating of “Hold” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $4.50.

A number of brokerages have recently issued reports on HRTX. Jefferies Financial Group reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, November 4th. Zacks Research upgraded Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a report on Wednesday, October 8th.

Institutional Trading of Heron Therapeutics

Several large investors have recently added to or reduced their stakes in the company. B. Riley Wealth Advisors Inc. purchased a new position in shares of Heron Therapeutics during the second quarter valued at $26,000. R Squared Ltd purchased a new position in Heron Therapeutics during the 2nd quarter valued at about $26,000. PKS Advisory Services LLC acquired a new position in shares of Heron Therapeutics in the 3rd quarter valued at about $25,000. Russell Investments Group Ltd. purchased a new stake in shares of Heron Therapeutics in the second quarter worth approximately $43,000. Finally, Jones Financial Companies Lllp lifted its position in shares of Heron Therapeutics by 5,541.2% in the third quarter. Jones Financial Companies Lllp now owns 24,088 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 23,661 shares in the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Stock Down 4.5%

NASDAQ HRTX opened at $1.28 on Wednesday. Heron Therapeutics has a 12 month low of $1.00 and a 12 month high of $2.68. The company has a market capitalization of $234.70 million, a P/E ratio of -14.22 and a beta of 1.34. The company’s 50 day simple moving average is $1.21 and its 200 day simple moving average is $1.49. The company has a debt-to-equity ratio of 19.89, a current ratio of 2.56 and a quick ratio of 1.78.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The business had revenue of $38.21 million for the quarter, compared to analysts’ expectations of $39.03 million. Equities research analysts expect that Heron Therapeutics will post -0.13 earnings per share for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.